Court Opinion

ID: 4203773
Source: CourtListenerOpinion
Date Created: 2017-09-15 14:00:42.873253+00
Date Added: 2024-06-11T14:41:03.627156
License: Public Domain

16-1743
Pfizer Inc. v. McNeil-PPC, Inc.

                          UNITED STATES COURT OF APPEALS
                              FOR THE SECOND CIRCUIT

                                     SUMMARY ORDER

RULINGS BY SUMMARY ORDER DO NOT HAVE PRECEDENTIAL EFFECT.
CITATION TO A SUMMARY ORDER FILED ON OR AFTER JANUARY 1, 2007, IS
PERMITTED AND IS GOVERNED BY FEDERAL RULE OF APPELLATE
PROCEDURE 32.1 AND THIS COURT’S LOCAL RULE 32.1.1. WHEN CITING A
SUMMARY ORDER IN A DOCUMENT FILED WITH THIS COURT, A PARTY MUST
CITE EITHER THE FEDERAL APPENDIX OR AN ELECTRONIC DATABASE (WITH
THE NOTATION “SUMMARY ORDER”). A PARTY CITING A SUMMARY ORDER
MUST SERVE A COPY OF IT ON ANY PARTY NOT REPRESENTED BY COUNSEL.

      At a stated term of the United States Court of Appeals for the Second Circuit, held at the
Thurgood Marshall Courthouse, 40 Foley Square, in the City of New York, on the 15th day of
September, two thousand seventeen.

Present:
         ROBERT A. KATZMANN,
               Chief Judge,
         PETER W. HALL,
               Circuit Judge.*
________________________________________________

PFIZER INC.,

           Plaintiff-Counter-Defendant-Appellant,

                     v.                                            No. 16-1743

McNEIL-PPC, INC.,

         Defendant-Counter-Claimant-Appellee.
________________________________________________

*
 Judge Robert D. Sack, originally assigned to this panel, subsequently recused himself from this
case. Therefore, this case is decided by the two remaining members of the panel pursuant to
Second Circuit Internal Operating Procedure E(b).
                                                  1
For Plaintiff-Appellant:                              LYNN K. NEUNER (William T. Russell, Jr.,
                                                      and Daniel J. Stujenske, on the brief),
                                                      Simpson Thacher & Bartlett LLP, New
                                                      York, NY.

For Defendant-Appellee:                               STEVEN A. ZALESIN (Travis J. Tu, on the
                                                      brief), Patterson Belknap Webb & Tyler
                                                      LLP, New York, NY; Kathryn A. Meisel,
                                                      Johnson & Johnson, New Brunswick, NJ.

        Appeal from the United States District Court for the Southern District of New York

(Carter, J.).

        UPON DUE CONSIDERATION, IT IS HEREBY ORDERED, ADJUDGED, AND

DECREED that the judgment of the district court is VACATED, and the case is REMANDED

for further proceedings in accordance with this order.

        Pfizer Inc. appeals from the order of the United States District Court for the Southern

District of New York (Carter, J.), entered on April 27, 2016, granting the motion for judgment

on the pleadings under Federal Rule of Civil Procedure 12(c) filed by McNeil-PPC, Inc., and

denying Pfizer’s motion for judgment on the pleadings. The parties dispute the interpretation of a

consent judgment (the “Judgment”) entered in 1989 by Judge William Conner, then of the

United States District Court for the Southern District of New York. We assume the parties’

familiarity with the facts and procedural history of this case, as well as the issues on appeal.

        “We review a judgment under Federal Rule of Civil Procedure 12(c) de novo, accepting

the complaint’s factual allegations as true and drawing all reasonable inferences in the plaintiff’s

favor.” Kirkendall v. Halliburton, Inc., 707 F.3d 173, 178 (2d Cir. 2013). “A district court’s

interpretation of a consent decree is also subject to de novo review.” Pandora Media, Inc. v. Am.

Soc’y of Composers, Authors & Publishers, 785 F.3d 73, 77 (2d Cir. 2015) (per curiam).

                                                  2
“Consent decrees ‘reflect a contract between the parties (as well as a judicial pronouncement),

and ordinary rules of contract interpretation are generally applicable.’” U.S. ex rel. Anti-

Discrimination Ctr. of Metro N.Y., Inc. v. Westchester Cty., 712 F.3d 761, 767 (2d Cir. 2013)

(quoting Doe v. Pataki, 481 F.3d 69, 75 (2d Cir. 2007)). “[A] written agreement that is complete,

clear and unambiguous on its face must be enforced according to the plain meaning of its terms.”

In re World Trade Ctr. Disaster Site Litig., 754 F.3d 114, 122 (2d Cir. 2014). But “where the

contract language creates ambiguity, extrinsic evidence as to the parties’ intent may properly be

considered,” and “[w]here there is such extrinsic evidence, the meaning of the ambiguous

contract is a question of fact for the factfinder.” JA Apparel Corp. v. Abboud, 568 F.3d 390, 397

(2d Cir. 2009).

       In the instant case, the Judgment, as relevant here, enjoins Pfizer’s predecessor “from

stating in words or substance in any advertisement that ADVIL is ‘like TYLENOL’ in the

respect of adverse effects on the stomach.” J. App’x at 26. The question at issue in this litigation

is whether “ADVIL” in the Judgment refers to the Advil product for adults on the market during

the 1980s litigation, or to Advil products containing ibuprofen more generally, including Advil

products for children and infants. The Court looks first to whether the term “ADVIL” in the

Judgment is ambiguous, when taken together with Judge Conner’s opinion in McNeilab, Inc. v.

American Home Products Corp., 675 F. Supp. 819 (S.D.N.Y. 1987), which is incorporated by

reference in the Judgment. The Court agrees with the district court’s view that “[o]n its face

alone, the [Judgment] is ambiguous.” Pfizer Inc. v. McNeil-PPC, Inc., 183 F. Supp. 3d 491, 494

(S.D.N.Y. 2016). However, the Court disagrees that the judicial decision incorporated by

reference into the Judgment resolves this ambiguity, because that decision, like the Judgment

                                                  3
itself, can reasonably be read to apply either to all Advil products whose principal active

ingredient is ibuprofen or solely to the adult Advil that gave rise to the 1980s litigation. Because

the Judgment, when considered in light of the sole document it incorporates by reference,1 is

ambiguous as to whether the Judgment applies to pediatric Advil, the parties are entitled to offer

extrinsic evidence as to the parties’ intended meaning.

         We have considered all of the parties’ remaining arguments and have found in them no

basis for altering our decision. Accordingly, the judgment of the district court is VACATED,

and the case is REMANDED to the district court for further proceedings in accordance with this

order.

                                          FOR THE COURT:
                                          CATHERINE O’HAGAN WOLFE, CLERK

1
 Contrary to the defendant’s argument, the Judgment does not also incorporate by reference a
prior decision in the 1980s litigation. See Am. Home Prods. Corp. v. Johnson & Johnson, 654 F.
Supp. 568 (S.D.N.Y. 1987). However, even if the Judgment were also to incorporate this
decision, the Judgment would be still be ambiguous as to whether it applies to the later-approved
pediatric Advil product at issue in the instant appeal.

                                                 4